From Analysis:
Gap 006 analysis (archived stub)
Analysis for knowledge gap 006 in the neurodegeneration domain.
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Pathological tau triggers cytosolic DNA release and mitochondrial DNA stress, activating cGAS-STING signaling in neurons and microglia. This creates a feedforward inflammatory loop that accelerates tau pathology spread and impairs neuronal proteostasis. Tier 1 translational feasibility with 5-8 year development timeline.
No AI visual card yet
Mechanism: TDP-43 proteinopathy leads to progressive nuclear depletion of functional TDP-43, causing widespread alternative splicing defects at synapses, part
Temporal Causality Assumption
The hypothesis assumes nuclear TDP-43 depletion drives splicing dysfunction rather than being a consequence of earlier upstream insults. This assumes causation from correlation—a foundational logical flaw. Nuclear depletion may be a compensatory response, an epiphenomenon, or a parallel process occurring alongside (not before) other pathogenic events.
Specificity Problem
TDP-43 regulates thousands of sp
| Hypothesis | Primary Modality | Feasibility Tier | Timeline | Cost Range |
|------------|------------------|------------------|----------|------------|
| 7. cGAS-STING/Tau | STING inhibitors | Tier 1 | 5-8 yr | $100-200M |
| 2. TREM2/DAM | Agonist antibodies | Tier 2 | 6-9 yr | $150-250M |
| 6. Astrocyte/GRN | MCT4 modulators | Tier 2 | 7-10 yr | $150-250M |
| 1. TDP-43/Splicing | ASOs | Tier 3 | 10-12 yr | $150-300M |
| 3. Lysosome/αSyn | TRPML1 agonists | Tier 3
{
"ranked_hypotheses": [
{
"title": "cGAS-STING Pathway Hyperactivation Mediates Tau Propagation",
"description": "Pathological tau triggers cytosolic DNA release and mitochondrial DNA stress, activating cGAS-STING signaling in neurons and microglia. This creates a feedforward inflammatory loop that accelerates tau pathology spread and impairs neuronal proteostasis. Tier 1 translational feasibility with 5-8 year development timeline.",
"target_gene": "cGAS (CGAS), STING (TMEM173)",
"dimension_scores": {
"evidence_strength": 0.76,
"novelty": 0.70,
No clinical trials data available
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
sess_SDA_2026_04_02_gap_2["sess_SDA-2026-04-02-gap-2026-04-01-gap-006_task_9aae8fc5"] -->|produced| SDA_2026_04_02_gap_2026_0["SDA-2026-04-02-gap-2026-04-01-gap-006"]
Reduced_MCT4_expression["Reduced MCT4 expression"] -.->|reduces| astrocyte_lactate_product["astrocyte lactate production"]
Reduced_lactate_productio["Reduced lactate production"] -.->|reduces| neuronal_glucose_uptake["neuronal glucose uptake"]
Type_I_interferon_respons["Type I interferon response"] -->|correlates with| AD_and_Pick_s_disease["AD and Pick's disease"]
TREM2_loss_of_function["TREM2 loss-of-function"] -->|impairs| DAM_transition["DAM transition"]
TREM2_deficiency["TREM2 deficiency"] -->|prevents| amyloid_plaque_phagocytos["amyloid plaque phagocytosis"]
Trem2_knockout["Trem2 knockout"] -->|increases| amyloid_seeding["amyloid seeding"]
TREM2_agonist_antibodies["TREM2-agonist antibodies"] -->|promotes| microglial_amyloid_uptake["microglial amyloid uptake"]
Progranulin_haploinsuffic["Progranulin haploinsufficiency"] -->|impairs| astrocyte_lactate_product_1["astrocyte lactate production"]
Progranulin_haploinsuffic_2["Progranulin haploinsufficiency"] -->|causes| FTD["FTD"]
cGAS_STING["cGAS-STING"] -->|activates| neuroinflammation["neuroinflammation"]
cGAS_STING_3["cGAS-STING"] -->|impairs| neuronal_proteostasis["neuronal proteostasis"]
style sess_SDA_2026_04_02_gap_2 fill:#4fc3f7,stroke:#333,color:#000
style SDA_2026_04_02_gap_2026_0 fill:#4fc3f7,stroke:#333,color:#000
style Reduced_MCT4_expression fill:#4fc3f7,stroke:#333,color:#000
style astrocyte_lactate_product fill:#4fc3f7,stroke:#333,color:#000
style Reduced_lactate_productio fill:#4fc3f7,stroke:#333,color:#000
style neuronal_glucose_uptake fill:#4fc3f7,stroke:#333,color:#000
style Type_I_interferon_respons fill:#81c784,stroke:#333,color:#000
style AD_and_Pick_s_disease fill:#ef5350,stroke:#333,color:#000
style TREM2_loss_of_function fill:#ce93d8,stroke:#333,color:#000
style DAM_transition fill:#4fc3f7,stroke:#333,color:#000
style TREM2_deficiency fill:#ce93d8,stroke:#333,color:#000
style amyloid_plaque_phagocytos fill:#4fc3f7,stroke:#333,color:#000
style Trem2_knockout fill:#ce93d8,stroke:#333,color:#000
style amyloid_seeding fill:#4fc3f7,stroke:#333,color:#000
style TREM2_agonist_antibodies fill:#4fc3f7,stroke:#333,color:#000
style microglial_amyloid_uptake fill:#4fc3f7,stroke:#333,color:#000
style Progranulin_haploinsuffic fill:#ce93d8,stroke:#333,color:#000
style astrocyte_lactate_product_1 fill:#4fc3f7,stroke:#333,color:#000
style Progranulin_haploinsuffic_2 fill:#ce93d8,stroke:#333,color:#000
style FTD fill:#ef5350,stroke:#333,color:#000
style cGAS_STING fill:#81c784,stroke:#333,color:#000
style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
style cGAS_STING_3 fill:#81c784,stroke:#333,color:#000
style neuronal_proteostasis fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-02 | archived
No comments yet. Be the first to comment!